Cross-Sector entity
All 1 tracked stories fall under one category: market-trends. Compass Pathways is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. COMP360 appears in 1 tracked Cross-Sector story from March 24, 2026.
1 verified story tracked
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Compass Pathways is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. COMP360 appears in 1 tracked Cross-Sector story from March 24, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering COMP360. Shared-story counts are live from our verified record — not editorial picks.
Anticipated Data Readout
Expected primary endpoint results for the COMP005 Phase 3 trial in TRD.
Fiscal Year End
Closed 2025 with a strategic focus on regulatory filing preparations.
Therapist Training Milestone
Completed training for over 500 facilitators to support Phase 3 delivery protocols.
Phase 3 Expansion
Compass increased the number of active clinical sites for COMP006 to over 50 globally.
Compass Pathways reported its full-year 2025 financial results, highlighting a strategic focus on its pivotal Phase 3 COMP360 program for treatment-resistant depression. With a cash runway extending into late 2026, the company is positioned for a critical year of clinical readouts and regulatory engagement.
Source: finanznachrichten.de · pharmiweb.com
